FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Karyopharm Therapeutics (KPTI)
-
-
-
-
-
-
-
Karyopharm completes endometrial cancer trial enrollment, reports Q1 results
-
-
-
-
-
-
-
RBC Capital defends Karyopharm Therapeutics (KPTI) amid 10pct premarket drop: 'We see upside potential'
-
-
-
-
-
-
-
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Announces 1:15 Reverse Share Split
-
-
-
-
-
-
-
Karyopharm Therapeutics Provides Endometrial Cancer Program Update
-
330,374 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

